Warning! GuruFocus detected
1 Medium warning sign
with 4114.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Synmosa Biopharma Corp
ISIN : TW0004114004
Description
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | 2.36 | |||||
| Interest Coverage | 12.48 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 3.43 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.7 | |||||
| 3-Year EBITDA Growth Rate | 0.9 | |||||
| 3-Year EPS without NRI Growth Rate | 3.4 | |||||
| 3-Year FCF Growth Rate | 39.6 | |||||
| 3-Year Book Growth Rate | 12.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.12 | |||||
| 9-Day RSI | 62.52 | |||||
| 14-Day RSI | 59.85 | |||||
| 3-1 Month Momentum % | -4.89 | |||||
| 6-1 Month Momentum % | -10.75 | |||||
| 12-1 Month Momentum % | -5.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.38 | |||||
| Quick Ratio | 1.54 | |||||
| Cash Ratio | 0.86 | |||||
| Days Inventory | 192.95 | |||||
| Days Sales Outstanding | 71.12 | |||||
| Days Payable | 48.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.75 | |||||
| Dividend Payout Ratio | 0.35 | |||||
| 3-Year Dividend Growth Rate | 60.4 | |||||
| Forward Dividend Yield % | 1.75 | |||||
| 5-Year Yield-on-Cost % | 9.48 | |||||
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 6.02 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.93 | |||||
| Operating Margin % | 13.38 | |||||
| Net Margin % | 13.36 | |||||
| FCF Margin % | 8.25 | |||||
| ROE % | 10.58 | |||||
| ROA % | 6.05 | |||||
| ROIC % | 5.75 | |||||
| 3-Year ROIIC % | 7153.75 | |||||
| ROC (Joel Greenblatt) % | 10.54 | |||||
| ROCE % | 7.83 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.28 | |||||
| Forward PE Ratio | 15.47 | |||||
| PE Ratio without NRI | 20.15 | |||||
| Shiller PE Ratio | 31.71 | |||||
| Price-to-Owner-Earnings | 19.87 | |||||
| PEG Ratio | 0.89 | |||||
| PS Ratio | 2.7 | |||||
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 2.22 | |||||
| Price-to-Free-Cash-Flow | 32.71 | |||||
| Price-to-Operating-Cash-Flow | 19.71 | |||||
| EV-to-EBIT | 23.53 | |||||
| EV-to-EBITDA | 16.2 | |||||
| EV-to-Revenue | 3.31 | |||||
| EV-to-FCF | 39.75 | |||||
| Price-to-GF-Value | 0.9 | |||||
| Price-to-Projected-FCF | 1.78 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.81 | |||||
| Price-to-Graham-Number | 1.41 | |||||
| Earnings Yield (Greenblatt) % | 4.26 | |||||
| FCF Yield % | 2.82 | |||||
| Forward Rate of Return (Yacktman) % | 21.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Synmosa Biopharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 5,375.323 | ||
| EPS (TTM) (NT$) | 1.689 | ||
| Beta | -0.33 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 1.48 | ||
| Volatility % | 10.56 | ||
| 14-Day RSI | 59.85 | ||
| 14-Day ATR (NT$) | 0.457437 | ||
| 20-Day SMA (NT$) | 33.5425 | ||
| 12-1 Month Momentum % | -5.72 | ||
| 52-Week Range (NT$) | 32.069596 - 38.135473 | ||
| Shares Outstanding (Mil) | 458.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Synmosa Biopharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Synmosa Biopharma Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Synmosa Biopharma Corp Frequently Asked Questions
What is Synmosa Biopharma Corp(ROCO:4114)'s stock price today?
The current price of ROCO:4114 is NT$34.25. The 52 week high of ROCO:4114 is NT$38.14 and 52 week low is NT$32.07.
When is next earnings date of Synmosa Biopharma Corp(ROCO:4114)?
The next earnings date of Synmosa Biopharma Corp(ROCO:4114) is .
Does Synmosa Biopharma Corp(ROCO:4114) pay dividends? If so, how much?
The Dividend Yield % of Synmosa Biopharma Corp(ROCO:4114) is 1.75% (As of Today), Highest Dividend Payout Ratio of Synmosa Biopharma Corp(ROCO:4114) was 7.5. The lowest was 0.09. And the median was 0.32. The Forward Dividend Yield % of Synmosa Biopharma Corp(ROCO:4114) is 1.75%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers